{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:53:17Z","timestamp":1793785997039,"version":"4.6.1"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium glucose co\u2010transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some have reported risk of below\u2010knee lower extremity (BKLE) amputation. This study examined the real\u2010world comparative effectiveness within the SGLT2i class and compared with non\u2010SGLT2i antihyperglycaemic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Data from 4 large US administrative claims databases were used to characterize risk and provide population\u2010level estimates of canagliflozin's effects on hospitalization for heart failure (HHF) and BKLE amputation vs other SGLT2i and non\u2010SGLT2i in T2DM patients. Comparative analyses using a propensity score\u2013adjusted new\u2010user cohort design examined relative hazards of outcomes across all new users and a subpopulation with established cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across the 4 databases (142\u2009800 new users of canagliflozin, 110\u2009897 new users of other SGLT2i, 460\u2009885 new users of non\u2010SGLT2i), the meta\u2010analytic hazard ratio estimate for HHF with canagliflozin vs non\u2010SGLT2i was 0.39 (95% CI, 0.26\u20100.60) in the on\u2010treatment analysis. The estimate for BKLE amputation with canagliflozin vs non\u2010SGLT2i was 0.75 (95% CI, 0.40\u20101.41) in the on\u2010treatment analysis and 1.01 (95% CI, 0.93\u20101.10) in the intent\u2010to\u2010treat analysis. Effects in the subpopulation with established cardiovascular disease were similar for both outcomes. No consistent differences were observed between canagliflozin and other SGLT2i.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large comprehensive analysis, canagliflozin and other SGLT2i demonstrated HHF benefits consistent with clinical trial data, but showed no increased risk of BKLE amputation vs non\u2010SGLT2i. HHF and BKLE amputation results were similar in the subpopulation with established cardiovascular disease. This study helps further characterize the potential benefits and harms of SGLT2i in routine clinical practice to complement evidence from clinical trials and prior observational studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13424","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T06:27:48Z","timestamp":1529908068000},"page":"2585-2597","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":176,"title":["Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non\u2010SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real\u2010world meta\u2010analysis of 4 observational databases (OBSERVE\u20104D)"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9727-2138","authenticated-orcid":false,"given":"Patrick B.","family":"Ryan","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Titusville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3876","authenticated-orcid":false,"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Department of Medicine  Chapel Hill North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-5361","authenticated-orcid":false,"given":"Martijn J.","family":"Schuemie","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Titusville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"DeFalco","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-2040","authenticated-orcid":false,"given":"Zhong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Titusville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-9657","authenticated-orcid":false,"given":"Paul E.","family":"Stang","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Titusville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-745X","authenticated-orcid":false,"given":"Jesse A.","family":"Berlin","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_6_3_1","unstructured":"NealB PerkovicV MahaffeyKW deZeeuwD FulcherG MatthewsDR. The Integrated Results of the CANVAS Program. Presented at: The 77th Scientific Sessions of the American Diabetes Association (ADA); June 12 2017; San Diego CA.https:\/\/professional.diabetes.org\/sites\/professional.diabetes.org\/files\/media\/2017_press_program_ppt_neal\u2010final.pdf. Accessed December 5 2017."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1551"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029190"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k119"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13115"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.031227"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5925"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0097-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1145\/2414416.2414791"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxt043"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25"},{"key":"e_1_2_6_15_1","volume-title":"Evidence Synthesis and Meta\u2010Analysis for Drug Safety: Report of CIOMS Working Group X","year":"2016"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:01:18Z","timestamp":1761865278000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/dom.13424"],"URL":"https:\/\/doi.org\/10.1111\/dom.13424","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"2018-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}